NCT07117175View on ClinicalTrials.gov

A Clinical Study to Evaluate the Safety and Efficacy of Anti-human CD 7 CAR-NK Cell Injection in Subjects With Relapsed and Refractory CD7-positive Hematological Malignancy

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

December 15, 2027

Study Completion Date

January 30, 2028

Conditions
ImmunologyHematologic MalignanciesCAR-NK
Interventions
DRUG

Anti-human CD7 CAR-NK cell injection

Administer anti-human CD7 CAR-NK cell injection on D0

Trial Locations (1)

200080

Shanghai General Hospital, Shanghai

All Listed Sponsors
lead

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

OTHER

NCT07117175 - A Clinical Study to Evaluate the Safety and Efficacy of Anti-human CD 7 CAR-NK Cell Injection in Subjects With Relapsed and Refractory CD7-positive Hematological Malignancy | Biotech Hunter | Biotech Hunter